← All trials
NCT05668455
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 25, 2022
- Primary completion
- Dec 25, 2024
- Completion date
- Feb 20, 2025
- First posted
- Dec 29, 2022
- Last posted
- Dec 29, 2022
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of RennesLead sponsor
- Laboratoires TheaCollaborator
- University of RennesSponsor investigator
- Government of FranceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.